Your shopping cart is currently empty

CTT2274 is a prodrug of MMAE. It consists of a prostate-specific membrane antigen (PSMA) binding scaffold, a biphenyl motif, a pH-sensitive phosphoramidate linker, and an MMAE payload. CTT2274 selectively targets and binds to PSMA to deliver MMAE and has the capability to inhibit prostate cancer.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | CTT2274 is a prodrug of MMAE. It consists of a prostate-specific membrane antigen (PSMA) binding scaffold, a biphenyl motif, a pH-sensitive phosphoramidate linker, and an MMAE payload. CTT2274 selectively targets and binds to PSMA to deliver MMAE and has the capability to inhibit prostate cancer. |
| Molecular Weight | 2417.58 |
| Formula | C119H159N17O33P2 |
| Smiles | CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)OC(=O)N(C)CCN(C)P(=O)(O)OCC[C@@H](C(=O)O)NC(=O)C4=CC=C(C=C4)CN5C6=C(C7=CC=CC=C7N(CC8=CC=CC=C86)C(=O)CCC(=O)N[C@@H](CC9=CC=C(C=C9)C1=CC=CC=C1)C(=O)NCCCCCC(=O)N[C@@H](CCC(=O)N[C@@H](CCCOP(=O)(N[C@@H](CCC(=O)O)C(=O)O)O)C(=O)O)C(=O)O)N=N5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.